JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258542

Human NRAS knockout HEK-293T cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

NRAS KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 5 bp deletion in exon 2 and 8 bp deletion in exon 2.
5 Images
Western blot - Human NRAS knockout HEK-293T cell lysate (AB258542)
  • WB

Lab

Western blot - Human NRAS knockout HEK-293T cell lysate (AB258542)

Lane 1 : Wild-type HEK-293T cell lysate 20 μg
Lane 2 : NRAS knockout HEK-293T cell lysate 20 μg
Lane 3 : MCF7 cell lysate 20 μg
Lane 4 : A549 cell lysate 20 μg
Lanes 1 - 4 : Merged signal (red and green). Green - ab198820 observed at 22 kDa. Red - loading control ab7291 (Mouse anti-Alpha Tubulin [DM1A]) observed at 55kDa.
ab198820 was shown to react with NRAS in wild-type HEK-293T cells in Western blot with loss of signal observed in NRAS knockout cell line ab266684 (NRAS knockout cell lysate ab258542). Wild-type HEK-293T and NRAS knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3 % milk in TBS-T (0.1 % Tween®) before incubation with ab198820 and ab7291 (Mouse anti-Alpha Tubulin [DM1A]) overnight at 4 °C at a 1 in 200 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 h at room temperature before imaging.

All lanes:

Western blot - Anti-NRAS antibody - C-terminal (<a href='/en-us/products/primary-antibodies/nras-antibody-c-terminal-ab198820'>ab198820</a>) at 1/200 dilution

Lane 1:

Wild-type HEK-293T cell lysate at 20 µg

Lane 2:

NRAS knockout HEK-293T cell lysate at 20 µg

Lane 2:

Western blot - Human NRAS knockout HEK-293T cell line (<a href='/en-us/products/cell-lines/human-nras-knockout-hek-293t-cell-line-ab266684'>ab266684</a>)

Lane 3:

MCF7 cell lysate at 20 µg

Lane 4:

A549 cell lysate at 20 µg

Predicted band size: 21 kDa

Observed band size: 22 kDa

false

Western blot - Human NRAS knockout HEK-293T cell lysate (AB258542)
  • WB

Lab

Western blot - Human NRAS knockout HEK-293T cell lysate (AB258542)

Lane 1 : Wild-type HEK-293T cell lysate 20 μg
Lane 2 : NRAS knockout HEK-293T cell lysate 20 μg
Lane 3 : MCF7 cell lysate 20 μg
Lane 4 : A549 cell lysate 20 μg
Lanes 1 - 4 : Merged signal (red and green). Green - ab167136 observed at 22 kDa. Red - loading control ab7291 (Mouse anti-Alpha Tubulin [DM1A]) observed at 55kDa.
ab167136 was shown to react with NRAS in wild-type HEK-293T cells in Western blot with loss of signal observed in NRAS knockout cell line ab266684 (NRAS knockout cell lysate ab258542). Wild-type HEK-293T and NRAS knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3 % milk in TBS-T (0.1 % Tween®) before incubation with ab167136 and ab7291 (Mouse anti-Alpha Tubulin [DM1A]) overnight at 4 °C at 0.5 μg/ml and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 h at room temperature before imaging.

All lanes:

Western blot - Anti-NRAS antibody (<a href='/en-us/products/primary-antibodies/nras-antibody-ab167136'>ab167136</a>) at 0.5 µg/mL

Lane 1:

Wild-type HEK-293T cell lysate at 20 µg

Lane 2:

NRAS knockout HEK-293T cell lysate at 20 µg

Lane 2:

Western blot - Human NRAS knockout HEK-293T cell line (<a href='/en-us/products/cell-lines/human-nras-knockout-hek-293t-cell-line-ab266684'>ab266684</a>)

Lane 3:

MCF7 cell lysate at 20 µg

Lane 4:

A549 cell lysate at 20 µg

Predicted band size: 21 kDa

Observed band size: 22 kDa

false

Western blot - Human NRAS knockout HEK-293T cell lysate (AB258542)
  • WB

Lab

Western blot - Human NRAS knockout HEK-293T cell lysate (AB258542)

Lane 1 : Wild-type HEK-293T cell lysate 20 μg
Lane 2 : NRAS knockout HEK-293T cell lysate 20 μg
Lane 3 : MCF7 cell lysate 20 μg
Lane 4 : A549 cell lysate 20 μg
False colour image of Western blot : Anti-NRAS antibody staining at 0.5 μg/ml, shown in green; Mouse anti-Alpha Tubulin [DM1A] (ab7291) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab167136 was shown to bind specifically to NRAS. A band was observed at 21 kDa in wild-type HEK-293T cell lysates with no signal observed at this size in NRAS CRISPR-Cas9 edited cell line ab266684 (NRAS CRISPR-Cas9 edited cell lysate ab258542). The band observed in the CRISPR-Cas9 edited lysate lane above 21 kDa is likely to represent NRAS with an insertion. This has not been investigated further and the functional properties of the gene product have not been determined. To generate this image, wild-type and NRAS CRISPR-Cas9 edited HEK-293T cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.

All lanes:

Western blot - Anti-NRAS antibody (<a href='/en-us/products/primary-antibodies/nras-antibody-ab167136'>ab167136</a>) at 0.5 µg/mL

Lane 1:

Wild-type HEK-293T cell lysate at 20 µg

Lane 2:

NRAS knockout HEK-293T cell lysate at 20 µg

Lane 3:

MCF7 cell lysate at 20 µg

Lane 4:

A549 cell lysate at 20 µg

Predicted band size: 21 kDa

Observed band size: 21 kDa

false

Sanger Sequencing - Human NRAS knockout HEK-293T cell lysate (AB258542)
  • Sanger seq

Unknown

Sanger Sequencing - Human NRAS knockout HEK-293T cell lysate (AB258542)

Allele-2 : 5 bp deletion in exon 2

Sanger Sequencing - Human NRAS knockout HEK-293T cell lysate (AB258542)
  • Sanger seq

Unknown

Sanger Sequencing - Human NRAS knockout HEK-293T cell lysate (AB258542)

Allele-1 : 8 bp deletion in exon 2

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, 5 bp deletion in exon 2 and 8 bp deletion in exon 2.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258542-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human NRAS knockout HEK293T cell lysate", "number":"AB258542-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HEK293T cell lysate", "number":"AB258542-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
NRAS
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The NRAS protein also known as neuroblastoma RAS viral oncogene homolog has a molecular weight of approximately 24 kDa. It functions mechanically as a GTPase cycling between an inactive GDP-bound state and an active GTP-bound state. The NRAS gene which encodes this protein shows expression in various tissues including the thymus leukocytes and other cells of the hematopoietic lineage. Activation of RAS involves the conversion to the GTP-bound form which enables NRAS to transmit signals within cells.
Biological function summary

NRAS plays an important role in cell proliferation differentiation and survival. It does not function alone but is part of the larger RAS protein family including HRAS and KRAS with whom it shares similar roles and sequence homology. NRAS interacts with various growth factor receptors and mediates signals to downstream effectors that influence cellular processes. Mutations in the NRAS gene can affect these biological processes leading to altered cell behavior.

Pathways

NRAS has significant roles in the MAPK/ERK pathway and the PI3K/AKT pathway. These pathways regulate fundamental cellular functions including growth and survival. NRAS interacts closely with other proteins such as RAF kinases and PI3K to propagate signals from activated receptors at the cell membrane to the nucleus. Altered NRAS activity can impact these pathways affecting cellular responses to external stimuli.

NRAS mutations are linked to certain cancers including melanoma and acute myeloid leukemia (AML). Mutant forms of NRAS result in constitutively activated RAS contributing to uncontrolled cell growth and survival. In melanoma NRAS mutations frequently co-occur with alterations in other proteins such as BRAF another member of the RAS/RAF/MEK/ERK pathway. Understanding NRAS's involvement in these conditions is critical for developing targeted therapeutic strategies.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com